Page URL: https://www.bionews.org.uk/page_92039

US approves first new stem cell lines

11 December 2009
Appeared in BioNews 538

Regulators in the US have approved 13 new human embryonic stem cell (ES cell)  lines - the first to be approved since President Obama lifted the restriction on stem cell research earlier this year in March. The 13 stem cell lines are the first the National Institutes of Health (NIH) has approved under the ethical guidelines that were unveiled in July; they are also the first new stem cells lines available to US scientists in almost a decade. It is hoped that the new lines, which are of a much better quality than the old lines, will lead to far more successful research.

In accordance with the ethical guidelines, these ES cell lines were derived using existing embryos left over from fertility treatment that would otherwise have been destroyed. The couples who created the embryos were given the option of donating them to other couples, to research (neither option can involve any financial incentive) or not donating them at all. Each couple gave full consent for the embryos to be used for research purposes.

The new lines were created using private funding, for although President Obama reversed former President George W Bush's restriction on federal funding for ES cell research, he was unable to lift the Dickey-Wicker amendment. This amendment prohibits the use of federal money to create stem cell lines, as doing so inevitably requires the destruction of an embryo. However, these new ES cell lines will qualify for millions of dollars in federal funding for research. Already, funding for approximately 30 proposals requiring human ES cells - totalling over $20 million - has been approved, confirms the NIH. Now that the stem cell lines are available, research can begin. Previously, federal funding was limited to 60 specific stem cell lines, all of which were created prior to 9 August 2001, when President Bush's restrictions were put in place.

Research involving the use of human ES cell lines remains controversial because it necessitates the destruction of human embryos, and reactions from the scientific and wider community have been mixed. In support, Amy Comstock Rick, President of the Coalition for the Advancement of Medical Research, commented that: 'it is incredibly rewarding for patients, advocates, and the scientific community to see embryonic stem cell research finally allowed to move forward, without arbitrary limitations, in our hopes of better treatments and cures for so many devastating diseases'. Professor George Daley, who created 11 of the 13 new stem cell lines - the other two were made by Ali Brivanlou at Rockerfeller University - has already hired three more technicians to assist in his research. 'It is a huge boost', he said, adding: 'It is a stimulus to my research'.

Others, however, have not greeted the news so enthusiastically. 'Ethically, we don't think any taxpayer should have to fund research that relies on destroying early human life at any stage', said Richard M Doerflinger of the US Conference of Catholic Bishops.

Francis Collins, Director of the NIH, noted that these new so-called 'ethical' stem cell lines represented a compromise position: 'I think the broad consensus among most of the public ... is that stem cell research of this ethically acceptable kind should go forward', he said. Some have questioned the need for stem cell lines derived from human embryos following recent breakthroughs in reprogramming ordinary cells to resemble stem cells (known as 'induced pluripotent stem cells (iPS cells)'). However, Collins commented that 'I think one could make a very strong case that we need both'.

A further 96 stem cell lines could soon be approved for research use. 'More lines are under review now', said Collins, adding that 'we anticipate continuing to expand this list of responsibly derived lines eligible for NIH funding'.

SOURCES & REFERENCES
NIH issues stamp of approval for new cell lines
Nature Blogs |  2 December 2009
Stem Cells: New policy reopens research funding
The Salt Lake Tribune |  3 December 2009
US approves 13 embryonic stem cell lines for research
BBC News |  2 December 2009
US approves 'ethical' human stem cell lines
The Telegraph |  3 December 2009
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
31 August 2010 - by Antony Starza-Allen 
A ruling of a district federal judge has halted federally-funded embryonic stem cell research in the United States...
4 May 2010 - by Dr Nadeem Shaikh 
US-based scientists working on embryonic stem cell (ES cell) research are relieved that the most important cell lines in their field have been approved for research by new government guidelines. During the Bush administration, US government funding for research involving ES cells was restricted to just 20 cell lines, all of which were in existence before 9 August 2001...
19 April 2010 - by Nishat Hyder 
Over a year since US President Barack Obama announced his decision to allow federal funding for embryonic stem cell research, the widely utilised cell lines, H9 and H7, are still weeks away from receiving federal funding approval. The H9 and H7 cell lines were derived and approved under the Bush administration and are currently owned by WiCell Research Institute in Madison, Wisconsin. However, for months now the fate of these two much used lines has been uncertain. According to...
1 March 2010 - by Dr Jay Stone 
The US National Institutes of Health (NIH) has proposed a broader definition of 'human embryonic stem cell' (HES), which would allow Federal funding of research using cells at an early development stage....
1 February 2010 - by Nishat Hyder 
The US National Institutes of Health (NIH) has approved the first human embryonic stem cell (ES) line from the George W Bush era, according to Nature News. It will be included on the National Stem Cell Registry (NSCR), ensuring its eligibility for federal funding....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.